Literature DB >> 23518714

Interferon β induces clearance of mutant ataxin 7 and improves locomotion in SCA7 knock-in mice.

Alice Chort1, Sandro Alves, Martina Marinello, Béatrice Dufresnois, Jean-Gabriel Dornbierer, Christelle Tesson, Morwena Latouche, Darren P Baker, Martine Barkats, Khalid H El Hachimi, Merle Ruberg, Alexandre Janer, Giovanni Stevanin, Alexis Brice, Annie Sittler.   

Abstract

We showed previously, in a cell model of spinocerebellar ataxia 7, that interferon beta induces the expression of PML protein and the formation of PML protein nuclear bodies that degrade mutant ataxin 7, suggesting that the cytokine, used to treat multiple sclerosis, might have therapeutic value in spinocerebellar ataxia 7. We now show that interferon beta also induces PML-dependent clearance of ataxin 7 in a preclinical model, SCA7(266Q/5Q) knock-in mice, and improves motor function. Interestingly, the presence of mutant ataxin 7 in the mice induces itself the expression of endogenous interferon beta and its receptor. Immunohistological studies in brains from two patients with spinocerebellar ataxia 7 confirmed that these modifications are also caused by the disease in humans. Interferon beta, administered intraperitoneally three times a week in the knock-in mice, was internalized with its receptor in Purkinje and other cells and translocated to the nucleus. The treatment induced PML protein expression and the formation of PML protein nuclear bodies and decreased mutant ataxin 7 in neuronal intranuclear inclusions, the hallmark of the disease. No reactive gliosis or other signs of toxicity were observed in the brain or internal organs. The performance of the SCA7(266Q/5Q) knock-in mice was significantly improved on two behavioural tests sensitive to cerebellar function: the Locotronic® Test of locomotor function and the Beam Walking Test of balance, motor coordination and fine movements, which are affected in patients with spinocerebellar ataxia 7. In addition to motor dysfunction, SCA7(266Q/5Q) mice present abnormalities in the retina as in patients: ataxin 7-positive neuronal intranuclear inclusions that were reduced by interferon beta treatment. Finally, since neuronal death does not occur in the cerebellum of SCA7(266Q/5Q) mice, we showed in primary cell cultures expressing mutant ataxin 7 that interferon beta treatment improves Purkinje cell survival.

Entities:  

Keywords:  CAG expansions; PML; SCA7; interferon beta; polyglutamine disease

Mesh:

Substances:

Year:  2013        PMID: 23518714     DOI: 10.1093/brain/awt061

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  22 in total

Review 1.  PML nuclear bodies: assembly and oxidative stress-sensitive sumoylation.

Authors:  Umut Sahin; Hugues de Thé; Valérie Lallemand-Breitenbach
Journal:  Nucleus       Date:  2014       Impact factor: 4.197

Review 2.  Dilemma of multiple system atrophy and spinocerebellar ataxias.

Authors:  Ming Li; Qianqian Ma; Xing Zhao; Can Wang; Huijie Wu; Jinyao Li; Wei Yang
Journal:  J Neurol       Date:  2018-04-26       Impact factor: 4.849

3.  Transplantation of Embryonic Cerebellar Grafts Improves Gait Parameters in Ataxic Lurcher Mice.

Authors:  Vaclav Babuska; Zbynek Houdek; Jan Tuma; Zdenka Purkartova; Jana Tumova; Milena Kralickova; Frantisek Vozeh; Jan Cendelin
Journal:  Cerebellum       Date:  2015-12       Impact factor: 3.847

Review 4.  Sumoylation in Physiology, Pathology and Therapy.

Authors:  Umut Sahin; Hugues de Thé; Valérie Lallemand-Breitenbach
Journal:  Cells       Date:  2022-02-26       Impact factor: 6.600

5.  Nonallele specific silencing of ataxin-7 improves disease phenotypes in a mouse model of SCA7.

Authors:  Pavitra S Ramachandran; Ryan L Boudreau; Kellie A Schaefer; Albert R La Spada; Beverly L Davidson
Journal:  Mol Ther       Date:  2014-06-16       Impact factor: 11.454

Review 6.  Transplantation and Stem Cell Therapy for Cerebellar Degenerations.

Authors:  Jan Cendelin
Journal:  Cerebellum       Date:  2016-02       Impact factor: 3.847

7.  PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes In Vivo.

Authors:  Joseph Ochaba; Alex Mas Monteys; Jacqueline G O'Rourke; Jack C Reidling; Joan S Steffan; Beverly L Davidson; Leslie M Thompson
Journal:  Neuron       Date:  2016-04-14       Impact factor: 17.173

8.  PML-NB-dependent type I interferon memory results in a restricted form of HSV latency.

Authors:  Jon B Suzich; Sean R Cuddy; Hiam Baidas; Sara Dochnal; Eugene Ke; Austin R Schinlever; Aleksandra Babnis; Chris Boutell; Anna R Cliffe
Journal:  EMBO Rep       Date:  2021-07-01       Impact factor: 9.071

Review 9.  From mice to men: lessons from mutant ataxic mice.

Authors:  Jan Cendelin
Journal:  Cerebellum Ataxias       Date:  2014-06-16

10.  Lack of Neuronal IFN-β-IFNAR Causes Lewy Body- and Parkinson's Disease-like Dementia.

Authors:  Patrick Ejlerskov; Jeanette Göransdotter Hultberg; JunYang Wang; Robert Carlsson; Malene Ambjørn; Martin Kuss; Yawei Liu; Giovanna Porcu; Kateryna Kolkova; Carsten Friis Rundsten; Karsten Ruscher; Bente Pakkenberg; Tobias Goldmann; Desiree Loreth; Marco Prinz; David C Rubinsztein; Shohreh Issazadeh-Navikas
Journal:  Cell       Date:  2015-10-08       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.